Quantcast
Last updated on April 20, 2014 at 7:48 EDT

Latest Myocardial perfusion imaging Stories

2013-05-17 12:23:32

- Study Presented at the Quality of Care and Outcomes Research 2013 Scientific Session - PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a clinical utility study of the Corus® CAD gene expression test in the real-world primary care setting for evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD). The multicenter, prospective...

2013-05-06 11:20:01

A new stress test protocol that investigates reducing the use of perfusion imaging in low risk patients undergoing SPECT myocardial perfusion imaging for possible angina symptoms was found to be diagnostically safe, revealed a US retrospective analysis. The study, reported as an abstract´ at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC11) May 5 to May 8 in Berlin, Germany, predicted that using exercise ECG stress testing alone in patients with high exercise...

2013-05-02 08:31:56

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors", authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer in the April issue of Molecular Therapy. The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the...

2013-04-25 08:35:04

- Corus CAD is the Only Clinically Validated Gene Expression Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., April 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced it has entered into an agreement granting to Core Diagnostics India the exclusive right to market and sell CardioDx's Corus(®) CAD diagnostic test in India. Corus CAD is a noninvasive blood-based gene expression...

2013-04-23 08:34:22

PALO ALTO, Calif., April 23, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 9:40 AM ET at the Westin Grand Central Hotel in New York. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for...

2013-04-03 12:30:22

WILMINGTON, Del., April 3, 2013 /PRNewswire/ -- Molecular Imaging Services, Inc. (MIS) is pleased to announce that it has performed the first Rubidium-82 Myocardial Perfusion PET scan in its newly opened office at Omega Medical Center located in Newark, Delaware. Myocardial Perfusion PET Imaging is a powerful tool in the assessment of coronary artery disease (CAD) and has been shown to have clear advantages over conventional SPECT Myocardial Perfusion Imaging. The higher sensitivity,...

2013-03-25 08:27:37

- Additional Data Underscore the Value of Corus CAD in Improving Primary Care Providers' (PCP) Precision at Excluding the Diagnosis of Obstructive Coronary Artery Disease in Female Patients Early in the Diagnostic Pathway - PALO ALTO, Calif., March 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced data demonstrating that Corus(®) CAD, the only clinically validated gene expression test for the assessment of...

2013-03-11 08:27:27

- Study Found that Cardiologists Changed Their Diagnostic Testing Strategy in 60 Percent of Female Patients Following Corus CAD Testing - PALO ALTO, Calif., March 11, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a prospective study that evaluated how Corus(®) CAD, a blood-based gene expression test, influenced cardiologists' patient management decisions in women with suspected obstructive coronary...

2013-03-04 08:29:07

PALO ALTO, Calif., March 4, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, announced that clinical data from studies of Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD), will be presented at the American College of Cardiology 62(nd) Annual Scientific Session taking place March 9-11, 2013 at the Moscone Center in San Francisco, CA. (Logo:...

2013-02-25 08:30:16

PALO ALTO, Calif., Feb. 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Cowen and Company 33(rd) Annual Healthcare Conference on Monday, March 4, 2013 at 10:00 a.m. ET at the Boston Marriott Copley Place in Boston. Andrew Guggenhime, the company's Chief Financial Officer, will provide an overview of CardioDx and Corus® CAD, the only clinically validated gene expression test...